Resverlogix (RVX) Competitors C$0.10 0.00 (0.00%) As of 03:49 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock RVX vs. SCYB, COM, NVH, IGX, MDNA, PDP, SVA, COV, EMH, and PMNShould you be buying Resverlogix stock or one of its competitors? The main competitors of Resverlogix include Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), Medicenna Therapeutics (MDNA), Pediapharm (PDP), Sernova (SVA), Covalon Technologies (COV), Emerald Health Therapeutics (EMH), and ProMIS Neurosciences (PMN). These companies are all part of the "biotechnology" industry. Resverlogix vs. Its Competitors Scythian Biosciences 138267 (COM.TO) Novoheart IntelGenx Technologies Medicenna Therapeutics Pediapharm Sernova Covalon Technologies Emerald Health Therapeutics ProMIS Neurosciences Scythian Biosciences (CVE:SCYB) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings. Is SCYB or RVX more profitable? Resverlogix's return on equity of 6.06% beat Scythian Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Scythian BiosciencesN/A N/A N/A Resverlogix N/A 6.06%-34.90% Do institutionals & insiders have more ownership in SCYB or RVX? 0.0% of Resverlogix shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has preferable valuation and earnings, SCYB or RVX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScythian BiosciencesN/AN/AN/AN/AN/AResverlogixN/AN/A-C$2.81M-C$0.04-2.63 Does the media prefer SCYB or RVX? In the previous week, Scythian Biosciences' average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score. Company Overall Sentiment Scythian Biosciences Neutral Resverlogix Neutral SummaryResverlogix beats Scythian Biosciences on 3 of the 4 factors compared between the two stocks. Get Resverlogix News Delivered to You Automatically Sign up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart RVX vs. The Competition Export to ExcelMetricResverlogixBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$30.08MC$233.59MC$6.16BC$9.71BDividend Yield7.02%3.80%5.66%6.47%P/E Ratio-2.6394.6985.5826.92Price / SalesN/A6,043.12612.6210.87Price / Cash132.5013.1926.3083.29Price / Book-0.45113.9212.875.77Net Income-C$2.81M-C$90.99MC$3.30BC$301.20M7 Day PerformanceN/A5.78%4.80%2.20%1 Month PerformanceN/A8.77%8.11%7.71%1 Year PerformanceN/A643.80%75.85%42.69% Resverlogix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVXResverlogixN/AC$0.11flatN/A+90.9%C$30.08MN/A-2.6319Gap DownHigh Trading VolumeSCYBScythian BiosciencesN/AC$3.49-5.9%N/A+0.0%C$102.38MN/A0.00N/AHigh Trading VolumeCOM138267 (COM.TO)N/AN/AN/AN/AC$102.19MN/A0.00N/ANVHNovoheartN/AC$0.53+1.9%N/A+0.0%C$99.98MC$423.50K-13.95N/AIGXIntelGenx TechnologiesN/AC$0.58+1.8%N/A+0.0%C$87.32MC$1.75M-7.442,050Gap UpMDNAMedicenna TherapeuticsN/AC$0.99-2.0%N/A-55.0%C$82.58MN/A-6.1920PDPPediapharmN/AC$0.30+1.7%N/A+0.0%C$66.36MC$11.16M-4.11N/ASVASernovaN/AC$0.19+5.6%N/A-26.9%C$62.45MN/A-3.801,959Gap DownCOVCovalon TechnologiesN/AC$2.11flatN/A-34.5%C$57.85MC$32.99M23.44N/AEMHEmerald Health TherapeuticsN/AC$0.26-3.8%N/A+0.0%C$52.28MC$13.02M-0.37161PMNProMIS NeurosciencesN/AN/AN/AN/AC$51.48MC$7.56K-1.786Gap UpHigh Trading Volume Related Companies and Tools Related Companies Scythian Biosciences Competitors 138267 (COM.TO) Competitors Novoheart Competitors IntelGenx Technologies Competitors Medicenna Therapeutics Competitors Pediapharm Competitors Sernova Competitors Covalon Technologies Competitors Emerald Health Therapeutics Competitors ProMIS Neurosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:RVX) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Resverlogix Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Resverlogix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
